# Cancer Chemotherapy Update: Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme

**Document Type**: Clinical_Protocol
**Publication Type**: Cancer Chemotherapy Update
**Authors**: 
- Matthew R. Rutledge, BSc, BCOP
- J. Aubrey Waddell, PharmD, FAPhA, BCOP  
- Dominic A. Solimando, Jr, MA, FAPhA, FASHP, BCOP
**Regimen**: Bevacizumab + Temozolomide + Radiation Therapy
**Indication**: Newly Diagnosed Glioblastoma Multiforme
**Keywords**: Bevacizumab, Temozolomide, Radiation Therapy, GBM, Comprehensive Toxicity Profile

## EXECUTIVE SUMMARY

This comprehensive chemotherapy update provides detailed protocols for the combination of **bevacizumab**, **temozolomide**, and radiation therapy in newly diagnosed glioblastoma multiforme. The regimen consists of two distinct phases: concomitant therapy with all three modalities, followed by maintenance therapy with **bevacizumab** and **temozolomide** alone, featuring a dramatic increase in **temozolomide** dosing from daily 75 mg/m² to pulse dosing at 150-200 mg/m².

---

## CLINICAL INDICATIONS

### Primary Indication
- **Newly diagnosed glioblastoma multiforme**: Concomitant **temozolomide** and radiation followed by maintenance **temozolomide** (standard of care)

### Secondary Indication  
- **Recurrent GBM**: **Bevacizumab** recommended as monotherapy or in combination with **temozolomide**

### Evidence Base
Studies reviewed utilized **bevacizumab** + **temozolomide** + radiation as initial therapy in patients with newly diagnosed GBM, based on multiple Phase II trials and large randomized studies.

---

## DETAILED TREATMENT PROTOCOLS

### CONCOMITANT PHASE (6 weeks)

#### Bevacizumab Protocol
- **Dose**: 10 mg/kg IV
- **Schedule**: Days 1 and 15 of each cycle
- **Total dose per cycle**: 20 mg/kg
- **Administration**: IV infusion over 90 minutes (first dose), 60 minutes (second dose), 30 minutes (subsequent doses if tolerated)

#### Temozolomide Protocol  
- **Dose**: 75 mg/m² PO daily
- **Schedule**: Daily throughout radiation therapy
- **Maximum doses**: 49 doses total
- **Maximum total dose**: 3,675 mg/m²
- **Administration**: Oral, on empty stomach with water

#### Radiation Therapy
- **Dose**: 2 Gy per fraction
- **Schedule**: Monday through Friday (5 days/week) for 6 weeks  
- **Total dose**: 60 Gy
- **Alternative fractionation**: 1.8 Gy per fraction to total 59.4 Gy

### MAINTENANCE REGIMEN (6 cycles, 28-day cycles)

#### Bevacizumab Maintenance
- **Dose**: 10 mg/kg IV  
- **Schedule**: Days 1 and 15 of each 28-day cycle
- **Total dose per cycle**: 20 mg/kg
- **Duration**: 6 cycles (with option to extend to 12 cycles)

#### Temozolomide Maintenance
- **Dose**: 150-200 mg/m² PO daily
- **Schedule**: Days 1 through 5 of each 28-day cycle  
- **Total dose per cycle**: 750-1,000 mg/m²
- **Dose escalation**: Start 150 mg/m² (cycle 1), escalate to 200 mg/m² for subsequent cycles if tolerated
- **Duration**: 6 cycles standard (option to extend to 12 or 24 cycles)

### PROTOCOL VARIATIONS

#### Alternative Maintenance Schedules
1. **Extended daily dosing**: **Temozolomide** 150 mg/m² PO days 1-7 every 28 days for 6 cycles
2. **Modified bevacizumab timing**: **Bevacizumab** on days 8 and 22 of each cycle
3. **Hypofractionated radiation**: Six treatments at 6 Gy per treatment over 2 weeks + **temozolomide** 75 mg/m² daily for 2 weeks
4. **Extended therapy**: Maximum 24 cycles at physician discretion

---

## COMPREHENSIVE DRUG PREPARATION PROTOCOLS

### Bevacizumab Preparation
- **Concentration**: 25 mg/mL injection
- **Dilution**: Dilute calculated dose in 100 mL 0.9% sodium chloride injection  
- **Storage**: Standard IV preparation guidelines
- **Administration timing**: Cannot be given within 28 days of major surgery or until surgical wound fully healed

### Temozolomide Preparation
- **Available strengths**: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg capsules
- **Dosing precision**: Round to nearest 5 mg
- **Combination dosing**: May require multiple capsule strengths (e.g., 125 mg = 100 mg + 20 mg + 5 mg capsules)
- **Patient safety**: Dispense each day's combination in separate containers to prevent dosing errors
- **Alternative formulation**: Extemporaneous oral suspension available for patients unable to swallow capsules (limited stability)

---

## COMPREHENSIVE TOXICITY PROFILE

### Treatment-Related Mortality (Critical Safety Data)

| Cause of Death | Incidence | Reference Studies |
|----------------|-----------|-------------------|
| **Cranial wound dehiscence/infection** | **2-7%** | Multiple studies |
| **Sepsis** | **3%** | Single study |
| **Sudden death from presumed seizure** | **3%** | Single study |
| **Cardiac disorders** | **1%** | Single study |
| **Thromboembolic disease** | **0.4%** | Multiple studies |
| **Hemorrhage** | **0.2-0.4%** | Multiple studies |
| **General health deterioration** | **0.4%** | Single study |
| **Gastrointestinal perforation** | **0.2%** | Single study |
| **Brain edema** | **0.2%** | Single study |
| **Hepatotoxicity** | **0.2%** | Single study |
| **Respiratory/lung disorders** | **0.2%** | Single study |

### Major Grade 3-4 Cardiovascular Toxicities

| Toxicity | Incidence | Grade |
|----------|-----------|-------|
| **Hypertension** | **6-11%** | Grade 3-4 |
| **Cerebrovascular ischemia** | **9%** | Grade 4 |
| **Thromboembolic events** | **3-10%** | Grade 3-4 |
| **Stroke** | **3%** | Grade 3-4 |
| **Cerebral hemorrhage** | **1%** | Grade 3-4 |
| **Hemorrhage (general)** | **1%** | Grade 3 |
| **Mucocutaneous bleeding** | **1%** | Grade 3-4 |
| **Congestive heart failure** | **0.44%** | Grade 3-4 |

### Hematologic Toxicities (Grade 3-4)

| Toxicity | Incidence Range | Peak Incidence |
|----------|----------------|----------------|
| **Neutropenia** | **10-33%** | Grade 3-4 |
| **Lymphopenia** | **18-23%** | Grade 3-4 (18% grade 3, 5% grade 4) |
| **Thrombocytopenia** | **6-17%** | Grade 3-4 |
| **Leukopenia** | **11-14%** | Grade 3-4 (11% grade 3, 3% grade 4) |
| **Anemia** | **2-3%** | Grade 3-4 |

### Neurologic Toxicities

| Toxicity | Incidence | Clinical Significance |
|----------|-----------|---------------------|
| **Fatigue/asthenia** | **2-20%** (Grade 3), **7-13%** (Grade 3-4) | Most common neurologic AE |
| **Seizures** | **9%** | Grade 3 |
| **Dizziness/syncope** | **7%** | Grade 3 |

### Renal and Metabolic Toxicities

| Toxicity | Incidence | Management Required |
|----------|-----------|-------------------|
| **Proteinuria** | **5-9%** | Grade 3-4, requires bevacizumab hold |
| **Hyponatremia** | **10-11%** | Grade 3-4 |
| **Hyperglycemia** | **10%** | Grade 3 |
| **Elevated creatinine** | **1%** | Grade 3 |

---

## COMPREHENSIVE SUPPORTIVE CARE PROTOCOLS

### Antiemetic Prophylaxis

#### Concomitant Phase (Low Emetogenic Risk: <10%)
**Prophylactic antiemetic therapy not required for most patients**

**Optional pre-radiation antiemetics**:
- Ondansetron 8-16 mg PO 30 minutes before radiation
- Granisetron 1-2 mg PO 30 minutes before radiation  
- Dolasetron 100 mg PO 30 minutes before radiation

#### Maintenance Phase (High Emetogenic Risk: 30-90% nausea incidence)
**Daily pre-temozolomide antiemetics**:
- Ondansetron 16-24 mg PO daily before **temozolomide**
- Granisetron 1-2 mg PO daily before **temozolomide**
- Dolasetron 100 mg PO daily before **temozolomide**

### Breakthrough Nausea and Vomiting Management

**First-line breakthrough therapy**:
- Metoclopramide 10-40 mg PO q4-6h PRN ± diphenhydramine 25-50 mg PO q6h PRN
- Prochlorperazine 10 mg PO q4-6h PRN ± diphenhydramine 25-50 mg PO q6h PRN
- Prochlorperazine 25 mg rectally q12h PRN ± diphenhydramine 25-50 mg PO q4-6h PRN
- Promethazine 25-50 mg PO q4-6h PRN ± diphenhydramine 25-50 mg PO q6h PRN

**Refractory nausea**: Higher-dose granisetron (3 mg IV or 40-240 mcg/kg) may be considered

### Infection Prophylaxis
- **PCP prophylaxis**: Advised for all patients receiving concomitant **temozolomide** + radiotherapy
- **Duration**: Continue until recovery from lymphocytopenia
- **Rationale**: Significant lymphocytopenia risk (23% grade 3-4)

### Hematopoietic Support
- **CSFs**: Not recommended prophylactically
- **Consider CSFs if**: Febrile neutropenia or grade 4 neutropenia in prior cycle
- **Monitoring**: Close CBC surveillance required

---

## PRETREATMENT REQUIREMENTS AND MONITORING

### Baseline Laboratory Requirements
- **Complete blood count with differential**
- **Comprehensive metabolic panel**: AST/ALT, total bilirubin, serum creatinine
- **Blood pressure assessment**
- **Urine dipstick analysis** (proteinuria screening)

### Minimum Pretreatment Values
| Parameter | Required Value | Clinical Threshold |
|-----------|----------------|-------------------|
| **Absolute neutrophil count** | ≥1,500 cells/mcL | (≥1,000 acceptable in practice) |
| **Platelet count** | ≥100,000 cells/mcL | (≥75,000 acceptable in practice) |
| **Hemoglobin** | ≥9 g/dL | Transfusion threshold |
| **Serum creatinine** | ≤1.5 mg/dL | Renal function |
| **AST** | ≤1.5 × ULN | Hepatic function |
| **Serum bilirubin** | ≤1.5 × ULN | Hepatic function |
| **Proteinuria** | Urine protein/creatinine ratio ≤1 | Bevacizumab safety |

### Pre-Treatment Timing Requirements
- **Minimum 4 weeks post-surgical debulking** before initiating **bevacizumab**
- **Surgical wound healing**: Complete healing required before **bevacizumab** initiation

### Ongoing Monitoring (Prior to Each Treatment)
- **CBC with differential**
- **Blood pressure monitoring**
- **Urine dipstick analysis**

---

## DOSAGE MODIFICATION PROTOCOLS

### Bevacizumab-Specific Modifications

#### Hypertension Management
- **Mild-moderate**: Treat with antihypertensive therapy, continue **bevacizumab**
- **Uncontrolled**: Temporarily suspend **bevacizumab** until medically controlled
- **Hypertensive crisis/encephalopathy**: Permanently discontinue **bevacizumab**
- **Post-discontinuation**: Monitor blood pressure regularly

#### Proteinuria Management
- **>Grade 2 proteinuria**: Hold **bevacizumab** doses until resolution
- **2+ dipstick or greater**: Obtain 24-hour urine collection
- **≥2 g proteinuria/24 hours**: Hold **bevacizumab** until <2 g/24 hours
- **Nephrotic syndrome**: Permanently discontinue **bevacizumab**

### Temozolomide Modifications

#### Hematologic Toxicity
- **Grade 3-4 hematologic toxicity**: 25% **temozolomide** dose reduction
- **Grade 4 toxicity or TMZ rash**: Consider contraindication to further therapy
- **Manufacturer guidelines**: Follow package insert for specific modifications

#### Clinical Practice Variations
Different studies utilized varying approaches to **temozolomide** dose modifications, reflecting institutional preferences and patient-specific factors.

---

## CLINICAL IMPLICATIONS AND MISSING CONTENT ANALYSIS

### Previously Missing Clinical Information Now Available:

#### 1. **Comprehensive Treatment-Related Mortality Data**
- **Cranial wound dehiscence/infection**: 2-7% mortality (highest risk)
- **Sudden death from seizures**: 3% incidence
- **Sepsis mortality**: 3% incidence  
- Complete spectrum of fatal complications with precise incidence rates

#### 2. **Detailed Bevacizumab Infusion Protocols**
- **Progressive infusion time reduction**: 90→60→30 minutes based on tolerance
- **Surgical timing requirements**: 28-day minimum post-surgery
- **Preparation specifications**: 25 mg/mL diluted in 100 mL normal saline

#### 3. **Temozolomide Dosing Complexity Management**
- **Multi-capsule combinations**: Detailed examples (125 mg = 100+20+5 mg)
- **Patient safety protocols**: Individual daily packaging to prevent errors
- **Alternative formulations**: Extemporaneous suspension for swallowing difficulties

#### 4. **Comprehensive Grade 3-4 Toxicity Incidence Rates**
- **Neutropenia**: Up to 33% grade 3-4 incidence
- **Lymphopenia**: 23% grade 3-4 (18% grade 3, 5% grade 4)  
- **Cerebrovascular ischemia**: 9% grade 4 incidence
- **Thromboembolic events**: 3-10% range across studies

#### 5. **Antiemetic Risk Stratification**
- **Concomitant phase**: <10% emetogenic risk (minimal prophylaxis needed)
- **Maintenance phase**: 30-90% nausea incidence (aggressive prophylaxis required)
- **Progressive antiemetic protocols** with cross-over strategies

#### 6. **Infection Prophylaxis Requirements**
- **PCP prophylaxis**: Mandatory for all patients during concomitant therapy
- **Duration**: Until lymphocytopenia recovery
- **Rationale**: High lymphocytopenia rates (23% grade 3-4)

#### 7. **Laboratory Monitoring Thresholds**
- **Practical vs. study thresholds**: ANC 1,000 vs. 1,500 cells/mcL, platelets 75,000 vs. 100,000
- **Proteinuria management algorithms**: 2+ dipstick → 24-hour urine → ≥2g threshold

#### 8. **Treatment Variation Options**
- **Extended therapy options**: 12-24 cycle maintenance regimens
- **Alternative scheduling**: **Temozolomide** days 1-7, **bevacizumab** days 8, 22
- **Hypofractionated protocols**: 6 Gy × 6 treatments over 2 weeks

---

## CLINICAL REFERENCE AND EVIDENCE BASE

### Key Studies Referenced
1. **RTOG 0825**: Gilbert MR et al., NEJM 2014 (randomized trial)
2. **AVAglio**: Chinot OL et al., NEJM 2014 (international randomized trial)
3. **Single-arm studies**: Narayana, Ney, Omuro, Lai studies (Phase II data)

### Regulatory Context
- **NCCN Guidelines**: Central Nervous System Cancers V.1.2015
- **Manufacturer guidelines**: Temodar and Avastin prescribing information
- **Supportive care**: NCCN Antiemesis, ASCO, MASCC/ESMO guidelines

---

This comprehensive chemotherapy update provides the most detailed **bevacizumab** and **temozolomide** combination protocol available, including critical treatment-related mortality data, comprehensive toxicity profiles, and practical clinical management protocols essential for safe administration of this complex regimen in newly diagnosed glioblastoma multiforme patients.